Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

August 7th 2025

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The analysis combined data from 3 major CLL clinical trials—ELEVATE-TN, ELEVATE-RR, and ASCEND—and postmarketing surveillance from a global database. | Image credit: laszlo - stock.adobe.com
Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data

July 31st 2025

Previous research suggests patients exposed to polypharmacy have greater risks of mortality, adverse drug reactions, and longer hospitalizations. | Image Credit: fizkes - stock.adobe.com
Number of Medications a Strong Prognostic Indicator in Lymphoma, CLL, MM

July 29th 2025

Older regimens for CLL were frequently used in older patients and were associated with significantly shorter overall survival, the authors found. | image credit: Saiful52 - stock.adobe.com
Newer Agents Should Be Used in First Line for Older Patients With CLL

July 28th 2025

Despite the benefits associated with adequate physical function in CLL, 70% of respondents said they had never received any physical activity advice from a doctor. | Image Credit: kieferpix - stock.adobe.com.jpg
Exercise Tied to Improved Symptoms, QOL in Patients With CLL

July 27th 2025

More News

Patient in a hospital bed with doctor | Image credit: Tyler Olson - stock.adobe.com
May 21st 2024

SID Heightens Infection Risk in Patients With B-Cell Malignancies

Jared Kaltwasser
A new report finds secondary immunodeficiency disease (SID) also increases the risk of mortality in patients with B-cell malignancies.
Liver scan by a robot | Image Credit: adisak-stock.adobe.com
May 21st 2024

Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL

Gayle Turim Dickstein
A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Ibrutinib Shows Similar Efficacy Across Trials in Chronic Lymphocytic Leukemia
May 17th 2024

Ibrutinib Shows Similar Efficacy Across Trials in Chronic Lymphocytic Leukemia

Luke Halpern
Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials.
Lymphoma word block image | Image Credit: airdone-stock.adobe.com
May 15th 2024

Important Insights Regarding Primary Breast Lymphoma

Luke Halpern
Due to the rarity of primary breast lymphoma, individualized treatment plans that consider overall health, symptoms, and patient preferences should be curated.
Nurse holding older woman's hands - Cecilie Arcurs/peopleimages.com - stock.adobe.com.jpeg
May 10th 2024

Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure

Gayle Turim Dickstein
The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Image of a doc reviewing a case report | Image Credit: fedrunovan - stock.adobe.com
May 8th 2024

CLL Followed by CML: A Rare Case Described

Gayle Turim Dickstein
A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of targeted kinase inhibitors.
Enhanced image of leukemia | Image Credit: freshidea - stock.adobe.com
May 2nd 2024

Targeted Therapies for CLL Can Lead to Improved Patient Outcomes

Luke Halpern
There was a marked increase in the prevalence of targeted therapy among patients with chronic lymphocytic leukemia (CLL), which corresponded to positive overall survival rates observed in the study.
Keyboard with a blue chronic lymphocytic leukemia key | Image credit: momius - stock.adobe.com
April 28th 2024

Targeted Combinations, Cellular Therapies, and Bispecific Antibodies Forge a New Path in CLL Management

Kimberly Rath, PharmD
An overview of the treatments for chronic lymphocytic leukemia (CLL) and novel therapies on the horizon, including double and triple combination therapies, cellular therapies, and bispecific antibodies.
CLL on a keyboard | Image Credit: momius - stock.adobe.com
April 26th 2024

Research Unveils UGT2B17 as Key Prognostic Marker in CLL

Kimberly Rath, PharmD
UGT2B17, a metabolic enzyme known for regulating various endogenous molecules, has been identified to have heightened expression in the B cells of patients who have chronic lymphocytic leukemia (CLL).
CLL cells in blood flow - Laszlo-stock.adobe.com
April 24th 2024

Long-Term, Real-World Data Support Ibrutinib Efficacy, Safety in CLL

Gayle Turim Dickstein
EVIdeNCE study data, from real-world practice, confirm the efficacy and safety that ibrutinib previously demonstrated in clinical trials involving patients with CLL, according to the study authors.
Leukemia word bubble | Image Credit: chrupka - stock.adobe.com
April 17th 2024

Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study

Kimberly Rath, PharmD
Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Older woman fatigue headache depression | Image Credit: © fizkes - stock.adobe.com
April 12th 2024

Nonpharmacological Approaches Lead to Significant Alleviation of CLL-Associated Fatigue

Jared Kaltwasser
Investigators said both reflexology and acupressure led to similar improvement in patients after 4 weeks.
White blood cells from leukemia | Image Credit: SebastianKaulitzki - stock.adobe.com
April 9th 2024

Venetoclax Monotherapy Leads to Durable Responses in Relapsed, Refractory CLL

Jared Kaltwasser
The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.
Broken arm in cast | Image credit: Thinapob - stock.adobe.com
April 5th 2024

Several Factors—but Not Osteoporosis—Increase Risk of Fractures in People With CLL

Jared Kaltwasser
Most fragility fractures experienced by people with chronic lymphocytic leukemia (CLL) are vertebral, the study found.
Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL
April 3rd 2024

Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL

Jared Kaltwasser
Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies.
Gene mutation | Image Credit: © Ilya-stock.adobe.com.jpeg
March 30th 2024

Review Chronicles Advancing Insights Into Epigenetic Alterations in Chronic Lymphocytic Leukemia

Luke Halpern
Studies of DNA methylation, RNA methylation, and histone modification revealed important information about the pathology of chronic lymphocytic leukemia and treatment potential.
Lymphoma graphic| Image Credit: MP Studio - stock.adobe.com
March 27th 2024

Study Supports Use of EORTC Item Library to Assess Lymphoma Symptoms

Luke Halpern
Clinician and patient interviews indicated satisfaction with the items presented to help describe patient symptoms with different lymphomas.
Abstract concept of scientific research | Image Credit: kras99 - stock.adobe.com
March 23rd 2024

Review Outlines Management of Patients Receiving Venetoclax for CLL

Jared Kaltwasser
Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.
Chronic lymphocytic leukemia | Image Credit: momius - stock.adobe.com
March 20th 2024

Quest to Advance CLL Therapy Operating on Multiple Fronts

Jared Kaltwasser
There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.
Bioinformatics and Health Informatics Concept Medical and Informatics Icons on Technology Background | Image credit: ArtemisDiana - stock.adobe.com
March 16th 2024

Genomics, Transcriptomics, and Epigenomics Utilized to Better Understand Chemoimmunotherapy Resistance in CLL

Luke Halpern
Advances in multi-omics have led to large scale studies that can provide a better prediction method for adequate therapy choices in patients with chronic lymphocytic leukemia (CLL).
Doctor holding a test blood sample tube with leukemia test on the background of medical test tubes with analyzes | Image Credit: syhin_stas stock.adobe.com
March 13th 2024

Molecular Mapping of CLL and Richter Syndrome Offers Crucial Insights

Luke Halpern
This new analysis provides an optimistic outlook on the future of chronic lymphocytic leukemia (CLL) treatment and discoveries into the background behind CLL transformation into Richter syndrome.
Older man with cough and cold | Image Credit: © sebra - stock.adobe.com
March 8th 2024

Case Report: COVID-19 Risk in CLL Could Be Exacerbated by Hypogammaglobulinemia

Jared Kaltwasser
The patient continued to test positive for COVID-19, but intravenous immunoglobulin eventually led to his recovery.
Man scratching a bug bite | Image credit: Oporty786 - stock.adobe.com
March 6th 2024

Case Report Shows Dupilumab Effective at Controlling Exaggerated Insect-Bite Response in Setting of CLL

Jared Kaltwasser
A patient with chronic lymphocytic leukemia (CLL) who experience persistent exaggerated responses to insect bites was successfully treated with dupilumab.
Patient and doctor | Image Credit: © DragonImages - stock.adobe.com
February 29th 2024

Treatment With iFRC and Ibrutinib Maintenance Led to Durable PFS in Patients With CLL

Luke Halpern
In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.
Cancer cell and lymphocytes | Image credit: Christoph Burgstedt-stock.adobe.com
February 28th 2024

CLL Cells Found to Secrete IL-9, Hindering Cytotoxic T-Cell Function

Jared Kaltwasser
Investigators say the findings could lead to new therapeutic targets.
Medication Management | Image Credit: © siripimon2525 - stock.adobe.com
February 24th 2024

Discontinuation of Ibrutinib Is Common in Older Patients With CLL, Study Finds

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.
Cancer care representation | Image credit: Nikki Zalewski - stock.adobe.com
February 19th 2024

Access to Cancer Care Alleviates Racial Disparities in CLL/SLL

Gwen Mergian
No difference in overall survival was observed between patients of different races who had chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and received cancer care or had access to a hematologist/oncologist.
Social Determinants of Health - STOATPHOTO - stock.adobe.com
February 16th 2024

Social Deprivation Independently Impacts Outcomes in Patients With Chronic Lymphocytic Leukemia

Luke Halpern
The study was the first of its kind to analyze social deprivation among CLL patients and observe the underlying reasons behind their clinical outcomes.
Lung imaging | Image credit: as-artmedia - stock.adobe.com
February 14th 2024

Mass-Like Opacities on Imaging Linked With LPI in CLL

Jared Kaltwasser
Ten of 13 patients with leukemic pulmonary infiltrates (LPI) and chronic lymphocytic leukemia (CLL) had single or multiple nodular/mass-like opacities, authors found.
Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma
February 11th 2024

Dr Ann LaCasce Discusses Potentially Game-Changing Treatments for Lymphoma

Rose McNulty
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology and chair of the Lymphoma Research Foundation’s scientific advisory board, discussed the changing lymphoma treatment landscape and highlighted potentially game changing treatments.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo